Related Experiment Video
Updated: Aug 13, 2026
Establishing 3-Dimensional Spheroids from Patient-Derived Tumor Samples and Evaluating their Sensitivity to Drugs
Published on: December 16, 2022
Idarubicin and idarubicinol effects on breast cancer multicellular spheroids
P Orlandi1, C Barbara, G Bocci
1Division of Pharmacology and Chemotherapy, Department of Internal Medicine, University of Pisa, Pisa, Italy.
Abstract:
Despite extensive preclinical evaluation in several experimental models, no studies have determined the effect of idarubicin and its metabolite idarubicinol on multicellular spheroids, a model which mimics the microregions of solid tumors. The principal aim of the present study was to investigate the in vitro cytotoxicity of idarubicin and its metabolite idarubicinol on MCF-7 breast cancer cells growing as monolayers or multicellular spheroids and to evaluate the influence of the length of exposure on the cytotoxic effect of both drugs. Cytoxicity was evaluated on monolayer and spheroid cultures exposed to idarubicin and idarubicinol 0.01-1000 ng/ml for 24 h or treated for 6, 12, 24 and 48 h to 100 ng/ml of both drugs. The IC50 of idarubicin and idarubicinol were 3.3+/-0.4 and 3.6+/-0.7 ng/ml, respectively, on MCF-7 monolayers and 7.9+/-1.1 and 5.3+/-0.7 ng/ml in multicellular spheroids, respectively. The antiproliferative effects of 100 ng/ml idarubicin and idarubicinol on MCF-7 spheroids was characterized by a marked time-dependence, which was less evident on MCF-7 growing as monolayer. In conclusion, the present experimental data demonstrate, for the first time, that idarubicin and idarubicinol have significant cytotoxic activity against multicellular spheroids, comparable to the antiproliferative effects on monolayer cells. In contrast, spheroids displayed substantial resistance after short exposure times that was not present in the two dimensional cultures.
Insights
This study reveals idarubicin and idarubicinol exhibit significant cytotoxicity against multicellular spheroids, mimicking solid tumors. Spheroids showed resistance to short drug exposures, unlike 2D cultures.
Area of Science:
- Pharmacology
- Cancer Biology
- Drug Discovery
Background:
- Multicellular spheroids mimic solid tumor microregions, but their response to idarubicin and idarubicinol is unstudied.
- Idarubicin and its metabolite idarubicinol are potent anticancer agents with established preclinical efficacy.
- Understanding drug response in 3D models is crucial for predicting in vivo efficacy.
Purpose of the Study:
- To investigate the in vitro cytotoxicity of idarubicin and idarubicinol on MCF-7 breast cancer cells.
- To compare drug effects on cells grown as monolayers versus multicellular spheroids.
- To evaluate the impact of drug exposure duration on cytotoxicity.
Main Methods:
- MCF-7 breast cancer cells were cultured as monolayers and multicellular spheroids.
- Cells were exposed to varying concentrations (0.01-1000 ng/ml) of idarubicin and idarubicinol for 24 hours.
- Cells were also treated with 100 ng/ml of each drug for 6, 12, 24, and 48 hours.
- Cytotoxicity was assessed by calculating IC50 values and evaluating time-dependent effects.
Main Results:
- IC50 values for idarubicin and idarubicinol were 3.3 and 3.6 ng/ml on monolayers, and 7.9 and 5.3 ng/ml on spheroids, respectively.
- A marked time-dependent antiproliferative effect was observed in spheroids, less pronounced in monolayers.
- Spheroids demonstrated significant resistance to short drug exposure times.
Conclusions:
- Idarubicin and idarubicinol possess significant cytotoxic activity against multicellular spheroids.
- Drug exposure duration critically influences the efficacy of these agents in 3D spheroid models.
- These findings highlight the importance of 3D models for evaluating anticancer drug efficacy and resistance mechanisms.
